HER-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification

Holly Zhou, R Randall, Arthur R. Brothman, Teresa Maxwell, Cheryl M. Coffin, Robert E. Goldsby

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

The purpose of this study was to investigate whether Her-2/neu expression at diagnosis of osteosarcoma could provide biologic and prognostic information that predicts the risk of pulmonary metastases and outcome. Human epidermal growth factor (Her-2/neu) expression in 25 initial pretreatment osteosarcoma biopsies and 12 posttreatment pulmonary metastatic osteosarcoma resection specimens was assessed by standard immunohistochemical techniques on formalin-fixed paraffin-embedded tissue. As a screening analysis to determine if gene amplification may be a mechanism for increased Her-2/neu expression, FISH analysis was conducted on seven Her-2/neu immunostain-positive samples and five Her-2/neu immunostain-negative samples. Cytoplasmic Her-2/neu reactivity was identified in 11/25 (44%) of primary tumors and in 7/12 (58%) resection specimens from pulmonary metastases. Cytoplasmic Her-2/neu expression was associated with shorter overall metastasis-free survival. Her-2/neu gene amplification was identified by FISH analysis in six of the seven immunostain-positive samples but was also identified in two of the five immunostain-negative samples. Her-2/neu expression in patients with osteosarcoma is associated with an increased risk of metastasis and may define a subset of patients with a more aggressive tumor phenotype. Her-2/neu gene amplification may provide a mechanism for Her-2/neu overexpression in certain cases of osteosarcoma. Whether Her-2/neu expression influences outcome needs to be examined further in a prospective fashion. The hope is that Her-2/neu expression will identify patients who may benefit from the addition of directed biologic therapy.

Original languageEnglish (US)
Pages (from-to)27-32
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume25
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Gene Amplification
Osteosarcoma
Neoplasm Metastasis
Lung
erbB-2 Genes
Biological Therapy
Epidermal Growth Factor
Paraffin
Formaldehyde
Neoplasms
Phenotype
Biopsy
Survival

Keywords

  • FISH analysis
  • Her-2/neu staining
  • Osteosarcoma
  • Pulmonary metastasis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

HER-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. / Zhou, Holly; Randall, R; Brothman, Arthur R.; Maxwell, Teresa; Coffin, Cheryl M.; Goldsby, Robert E.

In: Journal of Pediatric Hematology/Oncology, Vol. 25, No. 1, 01.01.2003, p. 27-32.

Research output: Contribution to journalArticle

Zhou, Holly ; Randall, R ; Brothman, Arthur R. ; Maxwell, Teresa ; Coffin, Cheryl M. ; Goldsby, Robert E. / HER-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. In: Journal of Pediatric Hematology/Oncology. 2003 ; Vol. 25, No. 1. pp. 27-32.
@article{25e34a2c4ea74dbe834fe6db16146712,
title = "HER-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification",
abstract = "The purpose of this study was to investigate whether Her-2/neu expression at diagnosis of osteosarcoma could provide biologic and prognostic information that predicts the risk of pulmonary metastases and outcome. Human epidermal growth factor (Her-2/neu) expression in 25 initial pretreatment osteosarcoma biopsies and 12 posttreatment pulmonary metastatic osteosarcoma resection specimens was assessed by standard immunohistochemical techniques on formalin-fixed paraffin-embedded tissue. As a screening analysis to determine if gene amplification may be a mechanism for increased Her-2/neu expression, FISH analysis was conducted on seven Her-2/neu immunostain-positive samples and five Her-2/neu immunostain-negative samples. Cytoplasmic Her-2/neu reactivity was identified in 11/25 (44{\%}) of primary tumors and in 7/12 (58{\%}) resection specimens from pulmonary metastases. Cytoplasmic Her-2/neu expression was associated with shorter overall metastasis-free survival. Her-2/neu gene amplification was identified by FISH analysis in six of the seven immunostain-positive samples but was also identified in two of the five immunostain-negative samples. Her-2/neu expression in patients with osteosarcoma is associated with an increased risk of metastasis and may define a subset of patients with a more aggressive tumor phenotype. Her-2/neu gene amplification may provide a mechanism for Her-2/neu overexpression in certain cases of osteosarcoma. Whether Her-2/neu expression influences outcome needs to be examined further in a prospective fashion. The hope is that Her-2/neu expression will identify patients who may benefit from the addition of directed biologic therapy.",
keywords = "FISH analysis, Her-2/neu staining, Osteosarcoma, Pulmonary metastasis",
author = "Holly Zhou and R Randall and Brothman, {Arthur R.} and Teresa Maxwell and Coffin, {Cheryl M.} and Goldsby, {Robert E.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1097/00043426-200301000-00007",
language = "English (US)",
volume = "25",
pages = "27--32",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - HER-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification

AU - Zhou, Holly

AU - Randall, R

AU - Brothman, Arthur R.

AU - Maxwell, Teresa

AU - Coffin, Cheryl M.

AU - Goldsby, Robert E.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The purpose of this study was to investigate whether Her-2/neu expression at diagnosis of osteosarcoma could provide biologic and prognostic information that predicts the risk of pulmonary metastases and outcome. Human epidermal growth factor (Her-2/neu) expression in 25 initial pretreatment osteosarcoma biopsies and 12 posttreatment pulmonary metastatic osteosarcoma resection specimens was assessed by standard immunohistochemical techniques on formalin-fixed paraffin-embedded tissue. As a screening analysis to determine if gene amplification may be a mechanism for increased Her-2/neu expression, FISH analysis was conducted on seven Her-2/neu immunostain-positive samples and five Her-2/neu immunostain-negative samples. Cytoplasmic Her-2/neu reactivity was identified in 11/25 (44%) of primary tumors and in 7/12 (58%) resection specimens from pulmonary metastases. Cytoplasmic Her-2/neu expression was associated with shorter overall metastasis-free survival. Her-2/neu gene amplification was identified by FISH analysis in six of the seven immunostain-positive samples but was also identified in two of the five immunostain-negative samples. Her-2/neu expression in patients with osteosarcoma is associated with an increased risk of metastasis and may define a subset of patients with a more aggressive tumor phenotype. Her-2/neu gene amplification may provide a mechanism for Her-2/neu overexpression in certain cases of osteosarcoma. Whether Her-2/neu expression influences outcome needs to be examined further in a prospective fashion. The hope is that Her-2/neu expression will identify patients who may benefit from the addition of directed biologic therapy.

AB - The purpose of this study was to investigate whether Her-2/neu expression at diagnosis of osteosarcoma could provide biologic and prognostic information that predicts the risk of pulmonary metastases and outcome. Human epidermal growth factor (Her-2/neu) expression in 25 initial pretreatment osteosarcoma biopsies and 12 posttreatment pulmonary metastatic osteosarcoma resection specimens was assessed by standard immunohistochemical techniques on formalin-fixed paraffin-embedded tissue. As a screening analysis to determine if gene amplification may be a mechanism for increased Her-2/neu expression, FISH analysis was conducted on seven Her-2/neu immunostain-positive samples and five Her-2/neu immunostain-negative samples. Cytoplasmic Her-2/neu reactivity was identified in 11/25 (44%) of primary tumors and in 7/12 (58%) resection specimens from pulmonary metastases. Cytoplasmic Her-2/neu expression was associated with shorter overall metastasis-free survival. Her-2/neu gene amplification was identified by FISH analysis in six of the seven immunostain-positive samples but was also identified in two of the five immunostain-negative samples. Her-2/neu expression in patients with osteosarcoma is associated with an increased risk of metastasis and may define a subset of patients with a more aggressive tumor phenotype. Her-2/neu gene amplification may provide a mechanism for Her-2/neu overexpression in certain cases of osteosarcoma. Whether Her-2/neu expression influences outcome needs to be examined further in a prospective fashion. The hope is that Her-2/neu expression will identify patients who may benefit from the addition of directed biologic therapy.

KW - FISH analysis

KW - Her-2/neu staining

KW - Osteosarcoma

KW - Pulmonary metastasis

UR - http://www.scopus.com/inward/record.url?scp=0037227104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037227104&partnerID=8YFLogxK

U2 - 10.1097/00043426-200301000-00007

DO - 10.1097/00043426-200301000-00007

M3 - Article

C2 - 12544770

AN - SCOPUS:0037227104

VL - 25

SP - 27

EP - 32

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 1

ER -